Ophthalmic Drugs Market
Ophthalmic Drugs Market Forecasts to 2028 – Global Analysis By Technology (Drug Delivery, Gene Therapy, Biologics, Small Molecule, Cell Therapy), End User (Specialty Clinics, Hospitals, Pharmacy), and By Geography
According to Stratistics MRC, the Global Ophthalmic Drugs market is accounted for $36.70 billion in 2020 and is expected to reach $70.49 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Some of the key factors propelling the market growth include rising R&D pertaining to the development of novel drugs, increasing focus on developing combination therapies, rising advancements in technologies, favorable reimbursement policies, increasing accessibility for healthcare facilities, and increasing incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. However, loss of patent protection for popular drugs is restraining the market growth.
Ophthalmic drugs are used to treat eye infection and various types of eye conditions. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. Ophthalmic diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, retinal vein occlusion (RVO), and myopic choroidal neovascularization, are potential threats to an individual’s sight. Ophthalmic drug forms have been one of the most important and widely developed areas of pharmaceutical technology over the few years.
By indication, the dry eye segment is anticipated to grow at the significant rate during the forecast period, increased dry eye cases among the peoples. Dry eye disease (DED) is a multifactorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to ageing, and hence, it remains an under-researched condition in the low- and middle-income countries. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the ageing population and the adoption of modern lifestyle.
On the basis of geography, the Asia Pacific is estimated to be the fastest-growing region in the market over the forecast period, due to increasing burden of ophthalmic disorders and rising consumer awareness. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the clinical and experimental vision and eye research, India, 2018. Moreover, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth.
Some of the key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.
|
Report Coverage |
Details |
|
Published Year: |
2021 |
|
Estimated Market Size in 2020: |
USD 36.70 billion |
|
Estimated Period: |
2020 |
|
Compound Annual Growth Rate (CAGR) from 2020 to 2028: |
8.5% |
|
Predicted 2028 Value: |
USD 70.49 billion |
|
Forecast Years: |
2021-2028 |
|
Tables, Graphs & Figures |
478 |
|
Chapters Covered: |
Type, Technology, Drug Variation, Indication, Distribution Channel, Route of Administration, Dosage Form, Delivery Type, Therapeutic Class, End User |
|
Core Drivers and Opportunities: |
|
|
Restraining Factors & Market Threats: |
|
Types Covered:
• Over-the-Counter Drugs
• Prescription Drugs
Technologies Covered:
• Drug Delivery
• Gene Therapy
• Biologics
• Small Molecule
• Cell Therapy
Drug Variations Covered:
• Generic Drugs
• Branded Drugs
Indications Covered:
• Glaucoma
• Dry Eye
• Cataract
• Retinal Disorders
• Uveitis
• Eye Infection/Inflammation/Eye Allergy
• Allergic Conjunctivitis
• Age-Related Macular Degeneration (AMD)
• Diabetic Eye Disease
• Other Indications
Distribution Channels Covered:
• Drug Stores
• Hospital Pharmacies
• Online Pharmacies
• Eye Health Clinics
• Retail Pharmacies/Independent Pharmacies
Route of Administrations Covered:
• Systemic
• Local Ocular
• Topical
• Oral
• Parenteral
Dosage Forms Covered:
• Solid Ophthalmic Drug Forms
• Liquid Ophthalmic Drug Forms
• Multicompartment Drug Delivery Systems
• Semisolid Ophthalmic Drug Forms
Delivery Types Covered:
• Eye Solutions
• Capsules & Tablets
• Eye Ointment
• Gels
• Eye Drops
Therapeutic Classes Covered:
• Anti-Inflammatory
• Antibiotics
• Anti-Allergy
• Anti-Glaucoma Drugs
• Anti-Angiogenic
• Anti-Infective Drugs
• Anti-Vascular Endothelial Growth Factor (VEGF) Agents
• Retinal Drug
• Other Therapeutic Classes (Cyclosporine)
End Users Covered:
• Specialty Clinics
• Hospitals
• Pharmacy
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2019, 2020, 2021, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Key Questions Answered In The Report
The Global Ophthalmic Drugs Market is majorly driven by increasing awareness regarding eye-related diseases, rising R&D pertaining to the development of novel drugs, increasing focus on developing combination therapies, and rising advancements in technologies.
The dry eye segment is growing at a highest CAGR owing to increased dry eye cases among the people, increasing proportion of the ageing population and the adoption of modern lifestyle.
North America dominated with a significant market share due to the factors such as the presence of excellent healthcare infrastructure and high consumer awareness.
Asia Pacific market is growing at a highest CAGR owing to increasing burden of ophthalmic disorders, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the region.
Key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Ophthalmic Drugs Market, By Type
5.1 Introduction
5.2 Over-the-Counter Drugs
5.3 Prescription Drugs
6 Global Ophthalmic Drugs Market, By Technology
6.1 Introduction
6.2 Drug Delivery
6.3 Gene Therapy
6.4 Biologics
6.5 Small Molecule
6.6 Cell Therapy
7 Global Ophthalmic Drugs Market, By Drug Variation
7.1 Introduction
7.2 Generic Drugs
7.3 Branded Drugs
8 Global Ophthalmic Drugs Market, By Indication
8.1 Introduction
8.2 Glaucoma
8.3 Dry Eye
8.4 Cataract
8.5 Retinal Disorders
8.5.1 Diabetic Retinopathy
8.5.2 Macular Degeneration
8.5.2.1 Dry Age-Related Macular Degeneration
8.5.2.2 Wet Age-Related Macular Degeneration
8.6 Uveitis
8.7 Eye Infection/Inflammation/Eye Allergy
8.8 Allergic Conjunctivitis
8.9 Age-Related Macular Degeneration (AMD)
8.10 Diabetic Eye Disease
8.11 Other Indications
8.11.1 Eyelash Hypotrichosis
8.11.2 Optic Neuropathy
9 Global Ophthalmic Drugs Market, By Distribution Channel
9.1 Introduction
9.2 Drug Stores
9.3 Hospital Pharmacies
9.4 Online Pharmacies
9.5 Eye Health Clinics
9.6 Retail Pharmacies/Independent Pharmacies
10 Global Ophthalmic Drugs Market, By Route of Administration
10.1 Introduction
10.2 Systemic
10.3 Local Ocular
10.3.1 Retrobulbar
10.3.2 Subconjunctival
10.3.3 Intracameral
10.3.4 Intravitreal
10.4 Topical
10.5 Oral
10.6 Parenteral
11 Global Ophthalmic Drugs Market, By Dosage Form
11.1 Introduction
11.2 Solid Ophthalmic Drug Forms
11.3 Liquid Ophthalmic Drug Forms
11.4 Multicompartment Drug Delivery Systems
11.5 Semisolid Ophthalmic Drug Forms
12 Global Ophthalmic Drugs Market, By Delivery Type
12.1 Introduction
12.2 Eye Solutions
12.3 Capsules & Tablets
12.4 Eye Ointment
12.5 Gels
12.6 Eye Drops
13 Global Ophthalmic Drugs Market, By Therapeutic Class
13.1 Introduction
13.2 Anti-Inflammatory
13.2.1 Steroidal Drugs
13.2.2 Non-Steroidal Anti-Inflammatory drugs (NSAIDs)
13.3 Antibiotics
13.4 Anti-Allergy
13.5 Anti-Glaucoma Drugs
13.5.1 Prostaglandin Analogs
13.5.2 Combined Medication
13.5.3 Alpha Agonist
13.5.4 Beta-Blockers
13.6 Anti-Angiogenic
13.7 Anti-Infective Drugs
13.7.1 Anti-Fungal Drugs
13.7.2 Anti-Bacterial Drugs
13.7.3 Anti-Viral Drugs
13.8 Anti-Vascular Endothelial Growth Factor (VEGF) Agents
13.9 Retinal Drug
13.10 Other Therapeutic Classes (Cyclosporine)
14 Global Ophthalmic Drugs Market, By End User
14.1 Introduction
14.2 Specialty Clinics
14.3 Hospitals
14.4 Pharmacy
15 Global Ophthalmic Drugs Market, By Geography
15.1 Introduction
15.2 North America
15.2.1 US
15.2.2 Canada
15.2.3 Mexico
15.3 Europe
15.3.1 Germany
15.3.2 UK
15.3.3 Italy
15.3.4 France
15.3.5 Spain
15.3.6 Rest of Europe
15.4 Asia Pacific
15.4.1 Japan
15.4.2 China
15.4.3 India
15.4.4 Australia
15.4.5 New Zealand
15.4.6 South Korea
15.4.7 Rest of Asia Pacific
15.5 South America
15.5.1 Argentina
15.5.2 Brazil
15.5.3 Chile
15.5.4 Rest of South America
15.6 Middle East & Africa
15.6.1 Saudi Arabia
15.6.2 UAE
15.6.3 Qatar
15.6.4 South Africa
15.6.5 Rest of Middle East & Africa
16 Key Developments
16.1 Agreements, Partnerships, Collaborations and Joint Ventures
16.2 Acquisitions & Mergers
16.3 New Product Launch
16.4 Expansions
16.5 Other Key Strategies
17 Company Profiling
17.1 Bayer AG
17.2 Abbott Healthcare
17.3 Merck & Co.
17.4 Pfizer, Inc.
17.5 Novartis AG
17.6 Valeant Pharmaceuticals, Inc.
17.7 Johnson & Johnson
17.8 Allergan Plc
17.9 Santen Pharmaceutical Co. Ltd.
17.10 Genentech, Inc.
17.11 F. Hoffmann-La Roche Ltd
17.12 Regeneron Pharmaceuticals Inc.
17.13 Aerie Pharmaceuticals Inc.
17.14 Bausch Health Companies Inc.
17.15 Carl-Zeiss AG
17.16 Hoya Corporation
List of Tables
1 Global Ophthalmic Drugs Market Outlook, By Region (2019-2028) ($MN)
2 Global Ophthalmic Drugs Market Outlook, By Type (2019-2028) ($MN)
3 Global Ophthalmic Drugs Market Outlook, By Over-the-Counter Drugs (2019-2028) ($MN)
4 Global Ophthalmic Drugs Market Outlook, By Prescription Drugs (2019-2028) ($MN)
5 Global Ophthalmic Drugs Market Outlook, By Technology (2019-2028) ($MN)
6 Global Ophthalmic Drugs Market Outlook, By Drug Delivery (2019-2028) ($MN)
7 Global Ophthalmic Drugs Market Outlook, By Gene Therapy (2019-2028) ($MN)
8 Global Ophthalmic Drugs Market Outlook, By Biologics (2019-2028) ($MN)
9 Global Ophthalmic Drugs Market Outlook, By Small Molecule (2019-2028) ($MN)
10 Global Ophthalmic Drugs Market Outlook, By Cell Therapy (2019-2028) ($MN)
11 Global Ophthalmic Drugs Market Outlook, By Drug Variation (2019-2028) ($MN)
12 Global Ophthalmic Drugs Market Outlook, By Generic Drugs (2019-2028) ($MN)
13 Global Ophthalmic Drugs Market Outlook, By Branded Drugs (2019-2028) ($MN)
14 Global Ophthalmic Drugs Market Outlook, By Indication (2019-2028) ($MN)
15 Global Ophthalmic Drugs Market Outlook, By Glaucoma (2019-2028) ($MN)
16 Global Ophthalmic Drugs Market Outlook, By Dry Eye (2019-2028) ($MN)
17 Global Ophthalmic Drugs Market Outlook, By Cataract (2019-2028) ($MN)
18 Global Ophthalmic Drugs Market Outlook, By Retinal Disorders (2019-2028) ($MN)
19 Global Ophthalmic Drugs Market Outlook, By Diabetic Retinopathy (2019-2028) ($MN)
20 Global Ophthalmic Drugs Market Outlook, By Macular Degeneration (2019-2028) ($MN)
21 Global Ophthalmic Drugs Market Outlook, By Uveitis (2019-2028) ($MN)
22 Global Ophthalmic Drugs Market Outlook, By Eye Infection/Inflammation/Eye Allergy (2019-2028) ($MN)
23 Global Ophthalmic Drugs Market Outlook, By Allergic Conjunctivitis (2019-2028) ($MN)
24 Global Ophthalmic Drugs Market Outlook, By Age-Related Macular Degeneration (AMD) (2019-2028) ($MN)
25 Global Ophthalmic Drugs Market Outlook, By Diabetic Eye Disease (2019-2028) ($MN)
26 Global Ophthalmic Drugs Market Outlook, By Other Indications (2019-2028) ($MN)
27 Global Ophthalmic Drugs Market Outlook, By Eyelash Hypotrichosis (2019-2028) ($MN)
28 Global Ophthalmic Drugs Market Outlook, By Optic Neuropathy (2019-2028) ($MN)
29 Global Ophthalmic Drugs Market Outlook, By Distribution Channel (2019-2028) ($MN)
30 Global Ophthalmic Drugs Market Outlook, By Drug Stores (2019-2028) ($MN)
31 Global Ophthalmic Drugs Market Outlook, By Hospital Pharmacies (2019-2028) ($MN)
32 Global Ophthalmic Drugs Market Outlook, By Online Pharmacies (2019-2028) ($MN)
33 Global Ophthalmic Drugs Market Outlook, By Eye Health Clinics (2019-2028) ($MN)
34 Global Ophthalmic Drugs Market Outlook, By Retail Pharmacies/Independent Pharmacies (2019-2028) ($MN)
35 Global Ophthalmic Drugs Market Outlook, By Route of Administration (2019-2028) ($MN)
36 Global Ophthalmic Drugs Market Outlook, By Systemic (2019-2028) ($MN)
37 Global Ophthalmic Drugs Market Outlook, By Local Ocular (2019-2028) ($MN)
38 Global Ophthalmic Drugs Market Outlook, By Retrobulbar (2019-2028) ($MN)
39 Global Ophthalmic Drugs Market Outlook, By Subconjunctival (2019-2028) ($MN)
40 Global Ophthalmic Drugs Market Outlook, By Intracameral (2019-2028) ($MN)
41 Global Ophthalmic Drugs Market Outlook, By Intravitreal (2019-2028) ($MN)
42 Global Ophthalmic Drugs Market Outlook, By Topical (2019-2028) ($MN)
43 Global Ophthalmic Drugs Market Outlook, By Oral (2019-2028) ($MN)
44 Global Ophthalmic Drugs Market Outlook, By Parenteral (2019-2028) ($MN)
45 Global Ophthalmic Drugs Market Outlook, By Dosage Form (2019-2028) ($MN)
46 Global Ophthalmic Drugs Market Outlook, By Solid Ophthalmic Drug Forms (2019-2028) ($MN)
47 Global Ophthalmic Drugs Market Outlook, By Liquid Ophthalmic Drug Forms (2019-2028) ($MN)
48 Global Ophthalmic Drugs Market Outlook, By Multicompartment Drug Delivery Systems (2019-2028) ($MN)
49 Global Ophthalmic Drugs Market Outlook, By Semisolid Ophthalmic Drug Forms (2019-2028) ($MN)
50 Global Ophthalmic Drugs Market Outlook, By Delivery Type (2019-2028) ($MN)
51 Global Ophthalmic Drugs Market Outlook, By Eye Solutions (2019-2028) ($MN)
52 Global Ophthalmic Drugs Market Outlook, By Capsules & Tablets (2019-2028) ($MN)
53 Global Ophthalmic Drugs Market Outlook, By Eye Ointment (2019-2028) ($MN)
54 Global Ophthalmic Drugs Market Outlook, By Gels (2019-2028) ($MN)
55 Global Ophthalmic Drugs Market Outlook, By Eye Drops (2019-2028) ($MN)
56 Global Ophthalmic Drugs Market Outlook, By Therapeutic Class (2019-2028) ($MN)
57 Global Ophthalmic Drugs Market Outlook, By Anti-Inflammatory (2019-2028) ($MN)
58 Global Ophthalmic Drugs Market Outlook, By Steroidal Drugs (2019-2028) ($MN)
59 Global Ophthalmic Drugs Market Outlook, By Non-Steroidal Anti-Inflammatory drugs (NSAIDs) (2019-2028) ($MN)
60 Global Ophthalmic Drugs Market Outlook, By Antibiotics (2019-2028) ($MN)
61 Global Ophthalmic Drugs Market Outlook, By Anti-Allergy (2019-2028) ($MN)
62 Global Ophthalmic Drugs Market Outlook, By Anti-Glaucoma Drugs (2019-2028) ($MN)
63 Global Ophthalmic Drugs Market Outlook, By Prostaglandin Analogs (2019-2028) ($MN)
64 Global Ophthalmic Drugs Market Outlook, By Combined Medication (2019-2028) ($MN)
65 Global Ophthalmic Drugs Market Outlook, By Alpha Agonist (2019-2028) ($MN)
66 Global Ophthalmic Drugs Market Outlook, By Beta-Blockers (2019-2028) ($MN)
67 Global Ophthalmic Drugs Market Outlook, By Anti-Angiogenic (2019-2028) ($MN)
68 Global Ophthalmic Drugs Market Outlook, By Anti-Infective Drugs (2019-2028) ($MN)
69 Global Ophthalmic Drugs Market Outlook, By Anti-Fungal Drugs (2019-2028) ($MN)
70 Global Ophthalmic Drugs Market Outlook, By Anti-Bacterial Drugs (2019-2028) ($MN)
71 Global Ophthalmic Drugs Market Outlook, By Anti-Viral Drugs (2019-2028) ($MN)
72 Global Ophthalmic Drugs Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) Agents (2019-2028) ($MN)
73 Global Ophthalmic Drugs Market Outlook, By Retinal Drug (2019-2028) ($MN)
74 Global Ophthalmic Drugs Market Outlook, By Other Therapeutic Classes (Cyclosporine) (2019-2028) ($MN)
75 Global Ophthalmic Drugs Market Outlook, By End User (2019-2028) ($MN)
76 Global Ophthalmic Drugs Market Outlook, By Specialty Clinics (2019-2028) ($MN)
77 Global Ophthalmic Drugs Market Outlook, By Hospitals (2019-2028) ($MN)
78 Global Ophthalmic Drugs Market Outlook, By Pharmacy (2019-2028) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
